Patents by Inventor Albert L. Dobi

Albert L. Dobi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ERG ONCOGENE INHIBITORS
    Publication number: 20230382862
    Abstract: The present disclosure relates generally to compounds suitable as ERG inhibitors, including compositions comprising such compounds, methods for their use in treating diseases associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation, and methods of making such compounds.
    Type: Application
    Filed: June 18, 2021
    Publication date: November 30, 2023
    Inventors: Albert L. Dobi, Sanjay Malhotra, Mallesh Pandrala
  • Azophenols as ERG oncogene inhibitors
    Patent number: 11648239
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 16, 2023
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
  • AZOPHENOLS AS ERG ONCOGENE INHIBITORS
    Publication number: 20210299106
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Application
    Filed: January 26, 2021
    Publication date: September 30, 2021
    Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
  • Azophenols as ERG Oncogene Inhibitors
    Publication number: 20190336485
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Application
    Filed: February 15, 2019
    Publication date: November 7, 2019
    Applicant: The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.
    Inventors: Albert L. DOBI, Clifton L. DALGARD, Shiv K. SRIVASTAVA
  • Azophenols as ERG oncogene inhibitors
    Patent number: 10238639
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 26, 2019
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
  • Azophenols as ERG Oncogene Inhibitors
    Publication number: 20180169074
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Application
    Filed: September 9, 2016
    Publication date: June 21, 2018
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Albert L. DOBI, Clifton L. DALGARD, Shiv K. SRIVASTAVA
  • PROSTATE CANCER-SPECIFIC ALTERATIONS IN ERG GENE EXPRESSION AND DETECTION AND TREATMENT METHODS BASED ON THOSE ALTERATIONS
    Publication number: 20160115481
    Abstract: Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1 and ERG genes.
    Type: Application
    Filed: October 30, 2015
    Publication date: April 28, 2016
    Inventors: Shiv K. Srivastava, Albert L. Dobi, Taduru Sreenath, Gyorgy Petrovics, Chen Sun